Loading stock data…
MNKD
$2.84+0.01 (+0.35%)
Market ClosedLast close May 1
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MannKind Corporation in the Healthcare sector is trading at $2.84. The stock is currently near its 52-week low of $2.23, remaining 38.5% below its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why MNKD maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.84
Potential Downside
96.2%
Whystock Fair Value$0.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$846.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
137.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.28%
Volume
Today's trading volume
2.80M
Recent News
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.72% and +50.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty
MannKind’s fair value estimate has been trimmed from US$7.50 to about US$7.17, a modest cut of roughly 4% that signals a slightly more cautious stance in updated models. This shift lines up with recent analyst commentary, where several firms have lowered price targets and at least one has moved to a more neutral rating as they reassess Tyvaso DPI royalties and the implications of United Therapeutics' soft mist inhaler plans. As you read on, you will see how both bullish and bearish voices are...
Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential
MannKind Corporation (NASDAQ:MNKD) is one of the best stocks under $5 with huge upside potential. Mizuho cut the price target on MannKind Corporation (NASDAQ:MNKD) to $8 from $10 on April 13 and reaffirmed an Outperform rating on the shares. The firm adjusted price targets and estimates for a number of stocks under its coverage in […]
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc. (NASDAQ:TBPH) to $17 from $14 on April 7, reiterating a Neutral rating on the shares. The firm told investors that the final generic settlement with MannKind Corporation locks exclusivity through […]
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development
MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare penny stocks to buy according to hedge funds. On March 30, Truist Securities reiterated that MannKind (NASDAQ:MNKD) is a Buy with a $7 price target in response to positive trial results from its strategic partner, United Therapeutics. MannKind has partnered with United Therapeutics to develop Tyvaso […]